Vivozon, an affiliate of Vivozon Pharmaceutical, announced on January 29 that it has received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for its new drug candidate 'VVZ-2471'.

Vivozon Receives FDA IND Approval for New Drug Candidate VVZ-2471 View original image

This IND approval pertains to a clinical trial conducted as part of a research project on opioid use disorder (OUD), supported by the National Institute on Drug Abuse (NIDA) under the U.S. National Institutes of Health (NIH). The clinical trial will be led by Virginia Commonwealth University (VCU). Opioid use disorder is more than just drug addiction; it refers to a 'chronic brain disease' in which the brain's reward circuitry is altered, making it impossible for individuals to quit drugs by willpower alone. As the administration of Donald Trump declared a war on drugs such as fentanyl, OUD has become one of the most important keywords in the biotech industry.


In Phase 1 of the clinical trial, the primary objective is to evaluate the safety and tolerability of repeated administration of VVZ-2471. This will provide the basis for dose setting and trial design for future clinical development in OUD patients, marking an important step in formulating subsequent development strategies.


VVZ-2471 is a first-in-class, non-narcotic therapeutic candidate with a dual mechanism of action that simultaneously modulates serotonin 2A receptors (5-HT2A) and metabotropic glutamate receptor 5 (mGluR5). It is based on a novel approach that targets the reward circuitry and craving regulation in the central nervous system.


Currently, a Phase 2 clinical trial is underway in Korea for the treatment of postherpetic neuralgia (PHN). Its clinical potential in the field of pain management is also being verified.



A Vivozon representative stated, "This FDA IND approval officially validates the clinical potential of VVZ-2471," adding, "We will gradually demonstrate its potential as a treatment for OUD through the VCU-led clinical trial."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing